Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes

PR Newswire

TORONTO, Nov. 17, 2026 /PRNewswire/ — Apotex Health Corp. (“Apotex” or the “Company”) (TSX: APTX), the largest Canadian-based global health company, today announced the launch of APO-LINAGLIPTIN™ (linagliptin tablets), the latest addition to its portfolio of medicines.

Apotex Inc. Logo

The launch expands treatment options for eligible adult patients living with type 2 diabetes mellitus and reflects Apotex’s ongoing commitment to improving everyday access to high-quality, affordable medicines for Canadians.

Monotherapy: APO-LINAGLIPTIN (linagliptin tablets) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance.1

Add-on combination: APO-LINAGLIPTIN (linagliptin tablets) is indicated for use in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with:

• metformin
• sulfonylurea (with or without metformin)
• metformin and empagliflozin
• basal insulin (with or without metformin)

when the therapy alone listed above, along with diet and exercise, does not provide adequate glycemic control.2

“The launch of APO-LINAGLIPTIN reflects our continued focus on providing Canadians with access to high-quality, affordable medicines and expanding treatment options across areas of ongoing healthcare need,” said Martin Arès, President, Apotex Canada and Rest of World. “As a proud Canadian company, we are committed to providing patients, healthcare professionals and payors with high-quality treatment options supported by reliable supply and affordability.”

Healthcare professionals should consult the complete APO-LINAGLIPTIN Product Monograph for detailed information on indications, dosing, contraindications, warnings, precautions, adverse reactions and patient monitoring requirements.

______________________________

1

Product Monograph: https://health-products.canada.ca/dpd-bdpp/?lang=eng

2

Product Monograph: https://health-products.canada.ca/dpd-bdpp/?lang=eng

About Apotex

Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

Learn more at www.apotex.com.

Forward-Looking Statements

This press release may contain forward-looking information within the meaning of applicable securities laws, including statements regarding Apotex expanding access to treatment options for patients living with type 2 diabetes, expanding treatment options for eligible adult patients living with type 2 diabetes mellitus, Apotex’s commitment to providing patients, healthcare professionals and payors with high-quality treatment options supported by reliable supply and affordability, Apotex’s commitment to improving everyday access to high-quality, affordable medicines for Canadians, and Apotex expanding treatment options across areas of ongoing healthcare need. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates, and projections regarding future events or circumstances. Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by the Company to be appropriate as of the date of this release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, risks associated with the Company being unable to expand access to treatment options or access for patients living with type 2 diabetes, Apotex being unable to meet its commitment to provide patients, healthcare professionals and payors with high-quality treatment options supported by reliable supply and affordability, the Company not being able to provide or improve access to high-quality, affordable medicines to Canadians or expand treatment options across areas of ongoing healthcare need, the Company’s ability to launch products on a timely basis, comply with applicable laws, meet regulatory requirements, maintain reliable supply and the factors discussed under “Risk Factors” in Apotex’s public filings. Apotex undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/apotex-launches-apo-linagliptin-expanding-access-to-treatment-options-for-canadians-living-with-type-2-diabetes-302942406.html

SOURCE Apotex Health Corp.

About The Author